⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL269445 | 0.86 | — | — | |
| SCHEMBL4687381 | 0.84 | GPR84 (0.35) | — | |
| SCHEMBL7172295 | 0.84 | MAOA (0.42) | — | |
| SCHEMBL499775 | 0.82 | GPR84 (0.38) | — | |
| SCHEMBL3391747 | 0.82 | GPR84 (0.38) | — | |
| SCHEMBL10538535 | 0.79 | MAOA (0.38) | — | |
| SCHEMBL7003873 | 0.79 | GPR84 (0.41) | — | |
| SCHEMBL211078 | 0.79 | — | — | |
| SCHEMBL79201 | 0.78 | MAOA (0.47) | — | |
| SCHEMBL25422764 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 287 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210316288-A1 | HYBRID MATERIAL AND METHOD FOR THE PRODUCTION THEREOF | UNIVERSITE PIERRE ET MARIE CURIE (FR) | 2021-10-14 | — | — | US | claimed |
| EP-1979355-B1 | SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2010-08-18 | — | — | EP | claimed |
| US-20090137610-A1 | SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2009-05-28 | — | — | US | claimed |
| EP-1979355-A1 | SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2008-10-15 | — | — | EP | claimed |
| WO-2007087448-A1 | SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2007-08-02 | — | — | WO | claimed |
| EP-0832898-A2 | Substituted amino acid derivatives | BAYER AG (DE) | 1998-04-01 | — | — | EP | claimed |
| EP-0825989-A1 | SUBSTITUTED OXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1998-03-04 | — | — | EP | claimed |
| WO-1996036617-A1 | SUBSTITUTED OXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-11-21 | — | — | WO | claimed |
| CN-108948019-B | Focal adhesion kinase inhibitors and uses thereof | 广东东阳光药业有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20210316288-A1 | HYBRID MATERIAL AND METHOD FOR THE PRODUCTION THEREOF | UNIVERSITE PIERRE ET MARIE CURIE (FR) | 2021-10-14 | — | — | US | disclosed |
| EP-3750892-A1 | NOVEL 5-CYCLOPROPYL-FURO[3,4-C]PYRIDINE-3,4(1H,5H)-DIONE 1,1' SUBSTITUTED DERIVATIVES AND THEIR USES | Yerevan State University (AM) | 2020-12-16 | — | — | EP | disclosed |
| US-10201525-B2 | Tetrazole-substituted arylamides as PX2 and PX2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2019-02-12 | — | — | US | disclosed |
| WO-2018209343-A1 | NOVEL METHODS, COMPOUNDS, AND COMPOSITIONS: SMALL MOLECULE ANTICANCER AGENTS | RAJUR SHARANAPPA BASAPPA (US) | 2018-11-15 | — | — | WO | disclosed |
| CN-108368606-A | The method of generation for thin inoranic membrane | 巴斯夫欧洲公司 | 2018-08-03 | — | — | CN | disclosed |
| WO-1996036617-A1 | SUBSTITUTED OXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-11-21 | — | — | WO | disclosed |
| WO-1996028418-A1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-19 | — | — | WO | disclosed |
| CN-1098716-A | Vasopressin antagonists and oxytocin antagonists | OTSUKA CHEMICAL CO LTD (JP) | 1995-02-15 | — | — | CN | disclosed |
| EP-0620003-A1 | VASOPRESSIN ANTAGONIST AND OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-19 | — | — | EP | disclosed |
| US-5321032-A | Peptide compounds and pharmaceutical compositions thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-14 | — | — | US | disclosed |
| EP-0515681-A1 | PEPTIDE COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-12-02 | — | — | EP | disclosed |